Business Wire

CSC and Palo Alto Networks Join Forces to Fortify Domain Security for Cortex XSOAR, XSIAM, and XPANSE Users and CSC Domain Registrar Clients

23.7.2024 16:00:00 EEST | Business Wire | Press release

Share

CSC, an enterprise-class domain registrar and world leader in mitigating domain security, domain name system (DNS), and digital brand threats, today announces a technical collaboration with Palo Alto Networks to boost domain security for users of Palo Alto Network’s Cortex XSOAR, XSIAM, and XPANSE solutions and for CSC's domain registrar clients. Under this collaboration, CSC will use domain name, DNS, and secure sockets layer (SSL) portfolio data—in conjunction with intelligence and capabilities within Cortex—to contextualize risks and facilitate the remediation of threats.

This new integration pack for our CSCDomainManager℠ application programming interface (API) is now available for download via the Cortex marketplace. As part of the relationship, joint Cortex and CSC clients can also benefit from a complimentary, defined package of domain name and URL phishing takedowns that target corporate domain name portfolios. This will help secure clients against threat vectors targeting their brands online—working to fortify their overall security posture.

“Given the increasing threats faced by organizations and their consumers due to brand impersonation and other DNS security issues, we're excited to extend CSC's robust data sets and solutions to our clients conveniently through their existing Cortex products. Going after malicious actors at their root via takedowns and ensuring proper DNS security to prevent hijacking and other risks are powerful proactive steps to prevent damaging security incidents,” says Andrew Scott, director of product at Palo Alto Networks.

“CSC detects domain threats, online brand and DNS abuse, and fraud to protect companies from cyberattacks caused by compromised or fraudulent domains,” says Mark Calandra, president of CSC's Digital Brand Services division. “Our inclusion in the Cortex marketplace is a testament to our capabilities and in-depth knowledge of the domain security landscape and boosts the visibility of our services by seamlessly integrating into the workflow of users focused on optimizing their cybersecurity posture.”

“In today’s ever-evolving cybersecurity landscape, integrating robust domain security and brand protection measures is not just a necessity, but a strategic imperative. Our collaboration with Palo Alto Networks exemplifies our commitment to delivering a comprehensive security posture that address the blended threats our clients face,” says Ihab Shraim, chief technology officer at CSC’s Digital Brand Services. “By leveraging advanced intelligence and capabilities, we empower businesses to proactively defend against domain-related cyber threats and ensure the integrity of their digital brand presence.”

Key benefits of the CSC and Cortex integration include:

  • Cortex XSOAR: Automates threat detection and incident response, simplifying management of domain-related security.
  • Cortex XSIAM: Analyzes data to identify vulnerabilities and enhances proactive threat mitigation strategies.
  • Cortex XPANSE: Provides visibility into and secures internet-facing assets, improving detection of vulnerable domains.
  • CSC Enhanced Domain Registrar Security: Strengthens defenses against hijacking, phishing and cyber threats. Implements continuous monitoring to protect against evolving domain security threats.

This partnership underscores the commitment of both CSC and Palo Alto Networks to deliver state-of-the-art security solutions, ensuring the safety and integrity of digital assets for their clients.

About CSC
CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands (Interbrand®) with focus areas in domain security and management, along with digital brand and fraud protection. As global companies make significant investments in their security posture, our DomainSec℠ platform can help them understand cybersecurity oversights that exist and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss. CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—with a multidimensional view of various threats outside the firewall targeting specific domains. Fraud protection services that combat phishing in the early stages of attack round out our solutions. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.

About Palo Alto Networks
Palo Alto Networks is the world's cybersecurity leader. We innovate to outpace cyberthreats, so organizations can embrace technology with confidence. We provide next-gen cybersecurity to thousands of customers globally, across all sectors. Our best-in-class cybersecurity platforms and services are backed by industry-leading threat intelligence and strengthened by state-of-the-art automation. Whether deploying our products to enable the Zero Trust Enterprise, responding to a security incident, or partnering to deliver better security outcomes through a world-class partner ecosystem, we're committed to helping ensure each day is safer than the one before. It's what makes us the cybersecurity partner of choice.

At Palo Alto Networks, we're committed to bringing together the very best people in service of our mission, so we're also proud to be the cybersecurity workplace of choice, recognized among Newsweek's Most Loved Workplaces (2023, 2022, 2021), with a score of 100 on the Disability Equality Index (2023, 2022), and HRC Best Places for LGBTQ+ Equality (2022). For more information, visit www.paloaltonetworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240723899433/en/

Contacts

Joyson Cherian
W2 Communications
CSC@w2comm.com
CSC® News Room -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fservice%2Fcsc%2Fpress%2F&esheet=54097829&newsitemid=20240723899433&lan=en-
US&anchor=CSC%26%23174%3B+News+Room&index=5&md5=172e8f1da9eacf4897deb50f6768ca5d

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 09:00:00 EET | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne capability sensor for armasui

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 08:00:00 EET | Press release

Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201157212/en/ “We pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions. We’re excited about the potential to bring this innovative neuromodulator to the U.S., offering advanced performance and ease of use and building on our portfolio of neuromodulators that meets the full spectrum of injecto

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 09:00:00 EET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 19:27:00 EET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye